Sharekhan is bullish on Ipca Laboratories has recommended buy rating on the stock with a target price of Rs 1135 in its research report dated April 30, 2019.
Sharekhan's research report on Ipca Laboratories
Resolution of the USFDA issues could provide a further upside. Strong outlook for 2-3 years, led by growth across key business verticals such as domestic formulations, APIs and institutional anti-malarial drugs. Despite USFDA issues being unresolved, the company is on a strong footing. We expect sales and profit to clock a CAGR of 20% and 28%, respectively over FY2019-FY2021.
We re-initiate coverage on Ipca with a Buy recommendation and a price target of Rs 1,135, valuing stock at 20x FY2021E earnings.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Get Lok Sabha 2019 Live Election Results, constituency-wise tally, news, views and analysis
Follow our Lok Sabha Election Result Live Blog here.